Weight-Based Dosing Versus a Fixed-Dose Regimen of 4-Factor Prothrombin Complex Concentrate in Obese Patients Requiring Vitamin K Antagonist Reversal

Introduction Despite an increase in the use of fixed-dose protocols of 4-factor prothrombin complex concentrate (4F-PCC) for the reversal of vitamin K antagonists (VKAs), there remains a paucity of data in obese patients. In this study, we aimed to compare the proportion of patients attaining intern...

Full description

Saved in:
Bibliographic Details
Published in:American journal of cardiovascular drugs : drugs, devices, and other interventions devices, and other interventions, 2021-05, Vol.21 (3), p.355-361
Main Authors: Elsamadisi, Pansy, Cepeda, Mark A. G., Yankama, Tuyen, Wong, Adrian, Tran, Qua, Eche, Ifeoma Mary
Format: Article
Language:English
Subjects:
Anticoagulants
Blood products
Cardiology
Drug administration
Drug dosages
FDA approval
Medicine
Medicine & Public Health
Original Research Article
Patients
Pharmacology/Toxicology
Pharmacotherapy
Surgery
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Introduction Despite an increase in the use of fixed-dose protocols of 4-factor prothrombin complex concentrate (4F-PCC) for the reversal of vitamin K antagonists (VKAs), there remains a paucity of data in obese patients. In this study, we aimed to compare the proportion of patients attaining international normalized ratio (INR) goals using a weight-based dosing strategy versus a fixed-dose regimen of 4F-PCC. Methods This was a retrospective study conducted in patients 18 years of age or older, weighing ≥ 100 kg, who received either a weight-based dose or fixed dose of 4F-PCC (2000 units) for the reversal of VKA, and had a documented baseline and post-treatment INR. The primary outcome was the proportion of patients achieving an INR of 
ISSN:1175-3277
1179-187X
DOI:10.1007/s40256-020-00442-w